Lead Product(s): Zalmoxis
Therapeutic Area: Oncology Product Name: Zalmoxis
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AGC Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 27, 2020
Through the acquisition of Molmed, AGC will enter into the innovative gene & cell therapy field to expand its CDMO offering to the area where there is a strong imbalance between demand and supply of specific skills and production capacity worldwide.